Revelation Biosciences In... (REVB)
| Bid | 1.29 |
| Market Cap | 2.26M |
| Revenue (ttm) | 26.96K |
| Net Income (ttm) | -8.46M |
| EPS (ttm) | 866.22 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.7 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 1.34 |
| Volume | 145,229 |
| Avg. Volume (20D) | 422,257 |
| Open | 1.36 |
| Previous Close | 1.36 |
| Day's Range | 1.30 - 1.40 |
| 52-Week Range | 1.27 - 60.48 |
| Beta | -0.11 |
| Ex-Dividend Date | n/a |
About REVB
undefined
1 month ago · accessnewswire.com
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross ProceedsSAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflamm...
1 month ago · accessnewswire.com
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - D...
1 month ago · accessnewswire.com
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line DataSAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflamma...
3 months ago · businesswire.com
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME StudySAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to op...